An inhaler article includes a body extending along a longitudinal axis from a mouthpiece end to a distal end and a capsule cavity defined within the body. A mouthpiece air channel extends from the capsule cavity to the mouthpiece end. An end cap is disposed within the distal end and extends to the capsule cavity. The end cap extends from an end cap distal end to an end cap inner end. The end cap includes an air channel extending from the end cap distal end to the end cap inner end. The air channel is non-parallel with the longitudinal axis.

A cavity authentication system for verifying at least one feature of a user using at least one acoustic signal, including an orifice element, including at least a signal opening and a reflection opening, an acoustic wave generator (AWG), an acoustic wave sensor (AWS), at least one output waveguide, at least one input waveguide, a processor, a memory and a power supply, the AWG for producing at least one acoustic signal, the AWS for receiving at least one reflection of the acoustic signal, the output waveguide for transmitting the acoustic signal to the user, the input waveguide for receiving the reflection of the acoustic signal, the memory configured to store cavity authentication data representative of the feature, wherein the processor is configured to analyze the reflection and to compare the analyzed reflection with the retrievable cavity authentication data and to generate an indication whether the analyzed reflection matches the retrievable cavity authentication data above a pre-determined threshold.

This disclosure provides nicotine-loaded microcapsules for use in treating or preventing nicotine dependence, or a withdrawal symptom thereof, in a subject in need thereof. The disclosure also provides pharmaceutical compositions and pharmaceutical formulations comprising nicotine-loaded microcapsules. The disclosure also provides methods of making nicotine-loaded microcapsules.

This disclosure provides nicotine-loaded microcapsules for use in treating or preventing nicotine dependence, or a withdrawal symptom thereof, in a subject in need thereof. The disclosure also provides pharmaceutical compositions and pharmaceutical formulations comprising nicotine-loaded microcapsules. The disclosure also provides methods of making nicotine-loaded microcapsules.

The embodiments disclose a method including creating a dual product vaporizer for use in vaping two different types of products at the same time, atomizing the two different types of products using two heaters for allowance of different burn temperatures for each of the two different types of products, wherein the two heaters are configured to operate at two different temperatures, wherein the two heaters are configured to operate at the same temperature, wherein the dual product vaporizer is configured to operate with only one product cartridge inserted, using at least one rechargeable battery to power the two heaters and an LED light battery indicator, and using two individual draw holes for drawing atomized product vapors from two individual product cartridges at the same time.

The invention relates to an oral nicotine formulation for use in the alleviation of nicotine craving, the formulation comprising a content of nicotine and a content of a pH regulating agent, wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 7.5 during the first 120 seconds upon oral administration.

The invention relates to an oral nicotine formulation for use in the alleviation of nicotine craving, the formulation comprising a content of nicotine and a content of a pH regulating agent, wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 7.5 during the first 120 seconds upon oral administration.

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

Provided is a composition, including: an aqueous suspension, comprising: a first plurality of active ingredients, and one or more nanoparticles, wherein: the one or more nanoparticles encapsulate a second plurality of active ingredients; the second plurality of active ingredients are insoluble in the aqueous suspension; the one or more nanoparticles solubilize the second plurality of active ingredients in the aqueous suspension; and the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers.